Acetazolamide Therapy for Hypochloremic Metabolic Alkalosis in Pediatric Patients With Heart Disease
- 1 July 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 14 (4), 331-335
- https://doi.org/10.1097/mjt.0b013e3180a72154
Abstract
Background: Pediatric patients with heart disease are often treated with high doses of diuretics, which can lead to hypochloremic metabolic alkalosis. There are no data in children regarding the efficacy and safety of acetazolamide to treat hypochloremic metabolic alkalosis. Methods: Patients from January 2004 to June 2005 who received acetazolamide were identified. Inclusion criteria were: age less than 18 years, being a cardiology patient, diuretics use, and had received a 3-day course of acetazolamide. Demographic information was collected along with serum electrolytes, serum creatinine/blood urea nitrogen, urine output, pH, acid-base excess, concurrent medications, cardiac lesion/surgery, and incidence of adverse effects. Efficacy of acetazolamide was determined by comparing variables before and after the 3-day course. Statistical comparisons were made using Student's t-test. Results: A total of 28 patients were identified, 7 of whom received oral acetazolamide, 21 intravenous acetazolamide. Patients were a median of 2.5 (range, 0.3-20) months of age, and 57% (17/28) were female. Seventy-one percent of the cohort received acetazolamide after cardiac surgery. There was no significant difference in any electrolyte, blood urea nitrogen, or serum creatinine from baseline, except for serum bicarbonate, which decreased (36.2 ± 4.6 vs. 30.9 ± 4.5 mmol/L, P < 0.001), and chloride, which increased (91.1 ± 6.8 vs. 95.4 ± 6.2, P < 0.03). Acid-base excess values and pH decreased during therapy in patients who had the laboratory values drawn (n = 22). No change in urine output at 8 hours (5.2 ± 2.3 vs. 4.9 ± 2.3 mL/kg/hr, P = 0.6) or 24 hours (4.7 ± 1.5 vs. 4.3 ± 1.4 mL/kg/hr, P = 0.18) occurred after administration of acetazolamide. Conclusion: Acetazolamide was safely used in pediatric patients with heart disease to lower serum bicarbonate and acid-base excess values and raise chloride values in hypochloremic metabolic alkalosis.Keywords
This publication has 13 references indexed in Scilit:
- Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patientsCritical Care, 2006
- Metabolic alkalosis after pediatric cardiac surgeryEuropean Journal of Cardio-Thoracic Surgery, 2005
- Risk factors prolonging ventilation in young children after cardiac surgery: Impact of noninfectious pulmonary complicationsPediatric Critical Care Medicine, 2002
- Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patientsCritical Care Medicine, 1999
- Metabolic Alkalosis in the Critically IIICritical Reviews in Clinical Laboratory Sciences, 1999
- Management of Life-Threatening Acid–Base DisordersNew England Journal of Medicine, 1998
- Metabolic alkalosis in children undergoing cardiac surgeryCritical Care Medicine, 1993
- Furosemide and Ethacrynic Acid: Risk Factors for the Occurrence of Serum Electrolyte Abnormalities and Metabolic Alkalosis in Newborns and InfantsActa Paediatrica, 1989
- Metabolic Alkalosis Complicating Weaning From Mechanical VentilationSouthern Medical Journal, 1979
- Treatment of alkalosis with ammonium chloride: A case reportClinical Pharmacology & Therapeutics, 1979